Market revenue in 2024 | USD 204.9 million |
Market revenue in 2030 | USD 574.5 million |
Growth rate | 18.7% (CAGR from 2024 to 2030) |
Largest segment | Upstream process |
Fastest growing segment | Downstream Process |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Upstream Process, Downstream Process, Process Development |
Key market players worldwide | Thermo Fisher Scientific Inc, Sartorius AG, Danaher Corp, Merck KGaA, Compagnie de Saint-Gobain SA, Corning Inc, Entegris Inc, Meissner, ProAnalytics, CellBios |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to bioprocess bags market will help companies and investors design strategic landscapes.
Upstream process was the largest segment with a revenue share of 44.41% in 2024. Horizon Databook has segmented the Japan bioprocess bags market based on upstream process, downstream process, process development covering the revenue growth of each sub-segment from 2018 to 2030.
Japan represents a well-developed healthcare industry with significant involvement of government bodies for the active promotion of biotechnology and related industries. The country is witnessing a demographic challenge as it is considered to have the oldest population in the world.
It acts as a catalyst and further drives the demand for biopharmaceutical development to ensure continuous medical supply. This, in turn, has resulted in the accelerated adoption of single-use technology. Japan is one of the major Asian markets for bioprocess bags.
Companies such as Takeda and Chugai are rapidly emerging in the field of biotech. For instance, in August 2020, Takeda announced a collaboration with Novavax for COVID-19 vaccine production in Japan for local commercialization. In addition, in January 2022, Merck signed a MoU with ID Pharma to fuel the development and manufacturing of gene therapy.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan bioprocess bags market , including forecasts for subscribers. This country databook contains high-level insights into Japan bioprocess bags market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account